Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOMS Extension
NCT00662649Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2008
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by Novartis. Primary endpoints: Annualized Aggregate Relapse Rate and Time to First Confirmed Relapse. Started Feb 2008; status: completed.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00662649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662649.